Abstract
Vaccination programs often focus on direct protection of vaccinated individuals against disease and discount reductions in transmission, which can result in preventable disease and death. Initial clinical trials for most COVID-19 vaccines only measured direct protection, and dosing and vaccine selection decisions have, so far, ignored effects on transmission. Here we provide a novel empirical framework for incorporating effects of COVID-19 vaccination on transmission in a continuous dynamic immune landscape. We quantified relationships between neutralizing antibody titers and vaccine effectiveness for both susceptibility (VES) and infectiousness (VEI) and quantified changes in VE with waning and boosting of immunity. We used these relationships to quantify the impact that additional doses of mRNA vaccines (BNT162b2 and mRNA-1273) could have had in reducing transmission and deaths caused by the deadliest SARS-CoV-2 variant, Delta, in Autumn 2021. Neutralizing antibodies waned 8-fold in 2021 over the six months following initial vaccination with mRNA vaccines, which reduced VES 33-38% (from 75-81% to 47-54%) and VEI 62-65% (from 47-57% to 16-22%) against the Delta variant. Third doses increased neutralizing antibody titers 13-26-fold, which more than restored VE and reduced the relative risk of transmission 7-10-fold. Administering third doses by September 1, 2021, could have reduced the effective reproductive number Rt by 19%, stopped surges in transmission in many populations, and averted an estimated 113,000 deaths in the United States, which is 2.6-12.4 fold higher than direct effects in vaccinated individuals. Vaccination programs that incorporate effects on transmission in trial design, vaccination frequency, and vaccine choice are needed to address current and future public health challenges.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the California Department of Health and the National Science Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Additional analyses were added to the manuscript to compare the direct and indirect effects of vaccination.
Data availability
All data used in the paper are contained in the supplemental material.
R Code and data files to replicate the figures and analyses of this paper are available: https://github.com/marmkilpatrick/Vaccine-boosters
Upon publication, R Code will be uploaded to Zenodo and data files will be archived with Dryad.
